[
  {
    "ts": null,
    "headline": "Molina Healthcare (MOH): Reassessing Valuation After Institutional Buying, Earnings Misses and Regulatory Uncertainty",
    "summary": "Molina Healthcare (MOH) is back in the spotlight after a wave of big money and big questions hit at once, with fresh institutional buying colliding with earnings disappointments, guidance cuts, and new legal scrutiny. See our latest analysis for Molina Healthcare. The stock has been whipsawed, with a recent bounce to a share price of $155.51 and a 7 day share price return of 7.25% coming after a bruising year to date share price return of 45.86 percent and a 1 year total shareholder return of...",
    "url": "https://finnhub.io/api/news?id=bd163fe4a41399932691c6a9adeaeb661c3f8247a420f5911c3ca924b15c8ad6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765318229,
      "headline": "Molina Healthcare (MOH): Reassessing Valuation After Institutional Buying, Earnings Misses and Regulatory Uncertainty",
      "id": 137751085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MOH",
      "source": "Yahoo",
      "summary": "Molina Healthcare (MOH) is back in the spotlight after a wave of big money and big questions hit at once, with fresh institutional buying colliding with earnings disappointments, guidance cuts, and new legal scrutiny. See our latest analysis for Molina Healthcare. The stock has been whipsawed, with a recent bounce to a share price of $155.51 and a 7 day share price return of 7.25% coming after a bruising year to date share price return of 45.86 percent and a 1 year total shareholder return of...",
      "url": "https://finnhub.io/api/news?id=bd163fe4a41399932691c6a9adeaeb661c3f8247a420f5911c3ca924b15c8ad6"
    }
  },
  {
    "ts": null,
    "headline": "Has Molina Healthcare’s 49% Slide Created an Opportunity After Recent Medicaid Contract Headlines?",
    "summary": "Wondering if Molina Healthcare is a beaten down bargain or a value trap at today’s price? You are not alone, and this breakdown will help you decide. The stock has bounced 7.2% over the last week and 2.3% over the past month, but those short term gains sit against a steep slide of 49.3% over the last year and 56.0% over three years, which has clearly shifted how the market is pricing in risk and growth. Recent headlines have focused on Molina’s role in Medicaid managed care and contract...",
    "url": "https://finnhub.io/api/news?id=d8e017597ce0941b20900e6864c3d2da2f6a74642cecf7200375eccfe8a4f2e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765314799,
      "headline": "Has Molina Healthcare’s 49% Slide Created an Opportunity After Recent Medicaid Contract Headlines?",
      "id": 137751086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MOH",
      "source": "Yahoo",
      "summary": "Wondering if Molina Healthcare is a beaten down bargain or a value trap at today’s price? You are not alone, and this breakdown will help you decide. The stock has bounced 7.2% over the last week and 2.3% over the past month, but those short term gains sit against a steep slide of 49.3% over the last year and 56.0% over three years, which has clearly shifted how the market is pricing in risk and growth. Recent headlines have focused on Molina’s role in Medicaid managed care and contract...",
      "url": "https://finnhub.io/api/news?id=d8e017597ce0941b20900e6864c3d2da2f6a74642cecf7200375eccfe8a4f2e6"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Stock Gains on Guidance Raise. How It Expects to Perform in 2025 and Beyond.",
    "summary": "CVS Health  issued an update to its full-year guidance Tuesday ahead of its annual investor day, pointing to stronger performance in 2025 than previously expected.  CVS now sees total revenue of at least $400 billion, up from $397.3 billion previously and above Wall Street’s forecast for $398.4 billion, according to FactSet.  The owner of the drugstore chain and insurance giant Aetna guided for adjusted earnings in the range of $6.60 to $6.70 a share, compared with a prior range of $6.55 to $6.65.",
    "url": "https://finnhub.io/api/news?id=379065bc105dc47ea32741a46f6dca0ed2366ae41d4965ae537891a494677b07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765283700,
      "headline": "CVS Health Stock Gains on Guidance Raise. How It Expects to Perform in 2025 and Beyond.",
      "id": 137740339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MOH",
      "source": "Yahoo",
      "summary": "CVS Health  issued an update to its full-year guidance Tuesday ahead of its annual investor day, pointing to stronger performance in 2025 than previously expected.  CVS now sees total revenue of at least $400 billion, up from $397.3 billion previously and above Wall Street’s forecast for $398.4 billion, according to FactSet.  The owner of the drugstore chain and insurance giant Aetna guided for adjusted earnings in the range of $6.60 to $6.70 a share, compared with a prior range of $6.55 to $6.65.",
      "url": "https://finnhub.io/api/news?id=379065bc105dc47ea32741a46f6dca0ed2366ae41d4965ae537891a494677b07"
    }
  }
]